0
0 (0%)
Cytodyn Inc. [CYDY]
Source:
Company Overview
Cytodyn Inc is a clinical stage biotechnology company focused on the clinical development and potential commercialization of its product candidate, leronlimab, which is being studied for oncology and inflammation, as well as other potential indications, including but not limited to HIV and MASH.
| Country | United States |
| Headquarters | vancouver, washington |
| Phone Number | 360-980-8524 |
| Industry | manufacturing |
| CEO | Jacob Lalezari |
| Website | www.cytodyn.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-4 |
| Net Income | $-4.8 |
| Net Cash | $0 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -29.4% |
| Profit as % of Stockholder Equity | 5.1% |
Management Effectiveness
| Return on Equity | 5.1% |
| Return on Assets | -22.5% |
| Turnover Ratio | |
| EBITA | $-4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $21.2 |
| Total Liabilities | $114.2 |
| Operating Cash Flow | $0 |
| Investing Cash Flow | |
| Financing Cash Flow | $0 |
